Belzutifan (Welireg™) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2α
being developed by Peloton Therapeutics for the treatment of solid tumours, including renal …

Aerobic exercise is an important non‐pharmacological means of antitumor intervention, but
related mechanisms are poorly understood. In this review, previous studies are summarized …

Radiotherapy as a standard method for cancer treatment faces tumor recurrence and
antitumoral unresponsiveness. Suppressive tumor microenvironment (TME) and hypoxia are …

To develop new chemotherapeutics with anti-metastasis properties, a series of multi-specific
niflumic acid (NFA) platinum (IV) complexes with DNA damage, inflammation inhibition …

Abstract Purpose of Review To review the biology, drug development, and clinical data
regarding the efficacy and safety of belzutifan (MK-6482), a small molecule inhibitor of HIF …

Hypoxia is a significant clinical feature and regulates various tumor processes in clear cell
renal carcinoma (ccRCC). Increasing evidence has demonstrated that long non-coding …

Objective. To establish and verify the clinical prediction model of lung metastasis in renal
cancer patients. Method. Kidney cancer patients from January 1, 2010, to December 31 …

Cancer is one of the diseases, which it is not still completely curable; the existing treatments
are associated with many complications, that double its complexity. One of the causes of …

Renal cell carcinoma (RCC) is a frequent urological malignancy characterized by a high rate
of metastasis and lethality. The treatment strategy for advanced RCC has moved through …

Background Hypoxia is an important clinical feature of glioblastoma (GBM), which regulates
a variety of tumor processes and is inseparable from radiotherapy. Accumulating evidence …